H3 K27M Variant DIPG (Diffuse Intrinsic Pontine Glioma) clinical trials
7 active DIPG (Diffuse Intrinsic Pontine Glioma) trials that test for H3 K27M Variant in their eligibility criteria. Describe your situation to see which ones look like a fit.
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
- Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository
← All DIPG (Diffuse Intrinsic Pontine Glioma) trials
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.